<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03812328</url>
  </required_header>
  <id_info>
    <org_study_id>SELK2-00005</org_study_id>
    <secondary_id>2018-003122-88</secondary_id>
    <nct_id>NCT03812328</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement</brief_title>
  <acronym>COURSE</acronym>
  <official_title>A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetherex Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tetherex Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if an investigational medication called SelK2
      works in preventing a condition called &quot;venous thromboembolism&quot; (VTE) in patients having a
      total knee replacement. SelK2 has been designed to attach to a protein found on blood cells
      and blood vessels. By attaching to this protein, SelK2 is designed to decrease the
      inflammatory process in the blood vessel wall that leads to the formation of blood clots in
      the vessel (called thrombosis). By decreasing the inflammatory process, SelK2 may reduce the
      risk of VTE following joint replacement surgery. In addition, because SelK2 is not a blood
      thinner, it is expected that the risk for bleeding will also be reduced.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The two arms of the study will enroll patients in a 2:1 ratio to receive either SelK2 with an active comparator or an active comparator only.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Total Venous Thromboembolism</measure>
    <time_frame>10 ± 2 Days After Total Knee Replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major or clinically relevant non-major bleeding events</measure>
    <time_frame>10 ± 2 Days After Total Knee Replacement</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>SelK2 and Enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SC, QD for up to 10 ± 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SelK2</intervention_name>
    <description>I.V., single-dose</description>
    <arm_group_label>SelK2 and Enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>SC, QD for up to 10 ± 2 days</description>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_label>SelK2 and Enoxaparin</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or females, 18-80 years of age (inclusive)

          -  Planned to undergo elective, primary total unilateral Total Knee Arthroplasty under
             general anesthesia

        Key Exclusion Criteria:

          -  Previous deep vein thrombosis (DVT) of the leg or pulmonary embolism (PE) within the
             past year

          -  Any underlying condition (e.g., atrial fibrillation, mechanical heart valve, or recent
             pulmonary embolism) that may lead to the required concomitant use of
             anticoagulants/antiplatelet agents (e.g., warfarin, dabigatran, rivaroxaban, apixaban,
             clopidogrel) that may affect study outcome or any other drug influencing coagulation
             (except low dose aspirin (100 mg or less))

          -  Anticipated use of intermittent pneumatic compression devices and/or
             electrical/mechanical muscle stimulators post Total Knee Arthroplasty procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Rother, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tetherex Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMHAT Kanev AD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsaritsa Yoanna - ISUL</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Liepaja</name>
      <address>
        <city>Liepāja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Traumatology and Orthopaedics</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORTO Clinic</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga's 2nd Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidzemes Hospital</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Clinical Hospital</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Bielsk Podlaski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Ogólny im. dr Witolda Ginela w Grajewie</name>
      <address>
        <city>Grajewo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Traumatology &amp; Orthopedics</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Regional Clinical Hospital</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venous thromboembolism</keyword>
  <keyword>adhesion molecule</keyword>
  <keyword>P-selectin glycoprotein ligand 1</keyword>
  <keyword>P-selectin</keyword>
  <keyword>venous thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

